
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is well positioned for long-term growth with a robust portfolio of marketed drugs and a strong pipeline of potential therapies for neurodegenerative and CNS diseases. The company's lead clinical candidate, ALKS 2680, has shown promising results in Phase 2b trials and has the potential to have a broad label for multiple indications. Additionally, the recent updates on the safety and efficacy profile of ALKS 2680 at the SLEEP conference further solidify the drug's strong profile, leading to an increase in the peak share for NT2 and raising the probability of success for narcolepsy treatment.
Bears say
Alkermes is facing stiff competition in the biotechnology industry, with catalyst-rich updates from its competitors such as VIBRANCE-3 IH data, ALKS 7190 Ph 1bin ADHD, and Cleminorexton's ongoing study for NT1/NT2. Despite potentially being second to market in NT1, management remains confident in its position, but this may indicate potential challenges in garnering physician and patient support for its products. Additionally, purchasing active drug products may strain Alkermes' finances and resources, leading to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares